Prospective Study of Fibrinolytic Factors and Incident Coronary Heart Disease
- 1 April 2001
- journal article
- other
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 21 (4) , 611-617
- https://doi.org/10.1161/01.atv.21.4.611
Abstract
Abstract —The fibrinolytic system may play a role in the pathogenesis of coronary heart disease (CHD), but existing prospective studies have not consistently shown an independent association between fibrinolytic factors and CHD. None has reported an association between plasminogen and CHD incidence. In the prospective Atherosclerosis Risk in Communities (ARIC) Study of middle-aged adults, we examined the association of incident CHD with several fibrinolytic factors: tissue plasminogen activator antigen, plasminogen activator inhibitor-1, plasminogen, and fibrin fragment D-dimer as well as a marker of coagulation activation (prothrombin fragment F1.2). We measured these in stored baseline plasma samples of 326 subjects who developed CHD and, for comparison, a stratified random sample of the entire cohort (n=720). Tissue plasminogen activator and plasminogen activator inhibitor-1 antigen levels were associated positively with CHD incidence in analyses adjusted for age, race, and sex but were not associated with CHD after adjustment for other risk factors. Plasminogen and D-dimer levels were associated positively and independently with CHD incidence; the multivariable-adjusted relative risks (95% CIs) for the highest versus lowest quintiles were 2.20 (1.2 to 4.2) for plasminogen and 4.21 (1.9 to 9.6) for D-dimer. F1.2 was not associated with CHD incidence. Our findings lend support for a link between fibrinolytic factors and CHD incidence. A positive association between plasminogen and CHD is seemingly opposite the direction expected but may reflect a compensatory response to impaired plasminogen activation in subjects prone to CHD.Keywords
This publication has 27 references indexed in Scilit:
- A Study of the Mechanism of Inhibition of Fibrinolysis by Activated Thrombin-activable Fibrinolysis InhibitorJournal of Biological Chemistry, 1998
- Expression and Induction by IL-6 of the Normal and Variant Genes for Human PlasminogenBiochemical and Biophysical Research Communications, 1997
- Prospective study of endogenous tissue plasminogen activator and risk of strokeThe Lancet, 1994
- Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart StudyThe Lancet, 1993
- Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart diseaseThe Lancet, 1993
- Endogenous tissue-type plasminogen activator and risk of myocardial infarctionThe Lancet, 1993
- PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTIONThe Lancet, 1987
- HAEMOSTATIC FUNCTION AND ISCHAEMIC HEART DISEASE: PRINCIPAL RESULTS OF THE NORTHWICK PARK HEART STUDYThe Lancet, 1986
- Fibrinogen as a Risk Factor for Stroke and Myocardial InfarctionNew England Journal of Medicine, 1984
- MONOCLONAL ANTIBODIES THAT REACT PREFERENTIALLY WITH FIBRINOGEN DEGRADATION PRODUCTS OR WITH CROSS‐LINKED FIBRIN SPLIT PRODUCTSAnnals of the New York Academy of Sciences, 1983